Keywords: diffuse large B‐cell lymphoma (DLBCL). Disclosures: Kurukulasuriya, N: Employment Leadership Position: MorphoSys US Inc. Menzler, J: Research Funding: Morphosys AG. Neubauer, A: Research Funding: Morphosys AG. Boehnke, A: Employment Leadership Position: MorphoSys AG....
Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP 来自 国家科技图书文献中心 喜欢 0 阅读量: 19 作者:HJ Kang,WS Kim,C Suh,YH Park,BS Kim,YJ Yuh,BY Ryoo ...
Diffuse-Large-B Cell Lymphoma CHOP: Cyclophosphamide, doxorubicin, vincristine, and prednisone RCHOP: Rituximab plus CHOP LYG: Life-year gained RCT: Randomized controlled trials NDFP: New Drug Funding Program OCR: Ontario Cancer Registry OHIP: Ontario Health Insurance Plan IPW: Inverse pr...
High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma,West China Hospital of Sichuan University,Observational,Not Applicable
Patients with an ICD-10-CM diagnosis for DLBCL after October 2015 and no prior ICD-9-CM diagnosis for unspecified DLBCL or primary mediastinal large B-cell lymphoma (PMBCL) where classified as incident; those with such codes were classified as prevalent. An adapted algorithm identified lines of...
doi:10.1200/JCO.2023.41.16_suppl.e195313e19531#Background:Central nervous system (CNS) relapse is an infrequent but serious and challenging complication in diffuse large B-cell lymphoma (DLBCL) that carries a dismal prognosis. While several risk factors have been identified to stratify the risk ...
The VHA is an equal access system providing a unique environment to investigate cancer disparities across the disease continuum.Methods:This is a retrospective chart review of 4033 randomly selected patients with an ICD code for lymphoma treated within the VHA between 01/01/2011 and 12/31/2017. ...
Venous-Thromboembolism in Elderly Patients with Diffuse Large B Cell LymphomaINTRODUCTION: Previous studies indicate that the risk of venous-thromboembolism (VTE) may be higher among patients with aggressive lymphoma. However, these studies were limited by small sample from single institutions and/or ...
The BLIMP1 locus is biallelically inactivated by structural alterations in approximately one third of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) (Pasqualucci et al, J Exp Med 2006). Moreover, the expression of the Blimp1 protein is absent in up to 80% of ABC-DLBCL ...
Incidence of any infections and SARS-CoV-2 infections in patients receiving treatment for follicular lymphoma and diffuse large B-cell lymphoma: Real-world evidence from a large US national claims database.doi:10.1200/JCO.2024.42.16_suppl.e19061...